Recarbrio – which based on established antibiotic combination imipenem/cilastatin with Merck’s new beta-lactamase ... director for the Office of Antimicrobial Products at the FDA, said that ...

Merck and Pfizer have received a major boost to their immune-oncology alliance with a second FDA Breakthrough Therapy Designation for Bavencio, this time in combination with Pfizer’s Inlyta.

The immune-related adverse events were higher for the fixed-dose combination than ... generate significant revenues for Merck over the long term. Both the products are witnessing a strong launch.

The companies are conducting pivotal phase III studies on V940, in combination with ... generate significant revenues for Merck over the long term. Both the products are witnessing a strong ...